Shlaes DM - Search Results

1

Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA. Perez F, et al. Among authors: shlaes dm. Clin Infect Dis. 2014 Mar;58(5):748-50. doi: 10.1093/cid/cit801. Epub 2013 Dec 12. Clin Infect Dis. 2014. PMID: 24336826 Free PMC article. No abstract available.

2

Emerging antimicrobial resistance and the immunocompromised host.

Shlaes DM, Binczewski B, Rice LB. Shlaes DM, et al. Clin Infect Dis. 1993 Nov;17 Suppl 2:S527-36. doi: 10.1093/clinids/17.supplement_2.s527. Clin Infect Dis. 1993. PMID: 8274620 Review.

3

Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.

Rice LB, Carias LL, Bonomo RA, Shlaes DM. Rice LB, et al. Among authors: shlaes dm. J Infect Dis. 1996 Jan;173(1):151-8. doi: 10.1093/infdis/173.1.151. J Infect Dis. 1996. PMID: 8537652

4

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Rice LB, Eckstein EC, DeVente J, Shlaes DM. Rice LB, et al. Among authors: shlaes dm. Clin Infect Dis. 1996 Jul;23(1):118-24. doi: 10.1093/clinids/23.1.118. Clin Infect Dis. 1996. PMID: 8816140

5

Vancomycin resistance in the enterococcus. Relevance in pediatrics.

Rice LB, Shlaes DM. Rice LB, et al. Among authors: shlaes dm. Pediatr Clin North Am. 1995 Jun;42(3):601-18. doi: 10.1016/s0031-3955(16)38981-7. Pediatr Clin North Am. 1995. PMID: 7761143 Review.

6

In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.

Rice LB, Carias LL, Shlaes DM. Rice LB, et al. Among authors: shlaes dm. Antimicrob Agents Chemother. 1994 Nov;38(11):2663-4. doi: 10.1128/AAC.38.11.2663. Antimicrob Agents Chemother. 1994. PMID: 7872765 Free PMC article.

7

Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.

Bonomo RA, Rudin SA, Shlaes DM. Bonomo RA, et al. Among authors: shlaes dm. FEMS Microbiol Lett. 1997 Mar 1;148(1):59-62. doi: 10.1111/j.1574-6968.1997.tb10267.x. FEMS Microbiol Lett. 1997. PMID: 9066111

8

Bacterial resistance to the cyclic glycopeptides.

Shlaes DM, Rice LB. Shlaes DM, et al. Trends Microbiol. 1994 Oct;2(10):385-8. doi: 10.1016/0966-842x(94)90616-5. Trends Microbiol. 1994. PMID: 7850206

9

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Infectious Diseases Society of America. Infectious Diseases Society of America. Clin Infect Dis. 2012 Oct;55(8):1031-46. doi: 10.1093/cid/cis688. Epub 2012 Aug 13. Clin Infect Dis. 2012. PMID: 22891041 Free PMC article.

10

Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.

Rice LB, Carias LL, Shlaes DM. Rice LB, et al. Among authors: shlaes dm. Antimicrob Agents Chemother. 1993 Mar;37(3):610-2. doi: 10.1128/AAC.37.3.610. Antimicrob Agents Chemother. 1993. PMID: 8460928 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters